Phase II study to evaluate the efficacy and tolerability of fulvestrant 250mg, 250mg (plus 250mg loading regimen) and 500mg in postmenopausal women with ER +ve advanced breast cancer progressing or relapsing after previous endocrine therapy.

Trial Profile

Phase II study to evaluate the efficacy and tolerability of fulvestrant 250mg, 250mg (plus 250mg loading regimen) and 500mg in postmenopausal women with ER +ve advanced breast cancer progressing or relapsing after previous endocrine therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms FINDER-I
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Feb 2012 Actual end date (1 Feb 2012) added as reported by ClinicalTrials.gov.
    • 14 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2011 Planned end date changed from 1 Aug 2009 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top